(BMEZ) BlackRock Health Sciences - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US09260E1055
Stock:
Total Rating 39
Risk 76
Buy Signal -0.11
| Risk 5d forecast | |
|---|---|
| Volatility | 17.2% |
| Relative Tail Risk | -2.49% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.26 |
| Alpha | -8.99 |
| Character TTM | |
|---|---|
| Beta | 0.697 |
| Beta Downside | 0.609 |
| Drawdowns 3y | |
|---|---|
| Max DD | 18.41% |
| CAGR/Max DD | 0.50 |
EPS (Earnings per Share)
Revenue
Description: BMEZ BlackRock Health Sciences
Headlines to watch out for
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 43.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 3.79 > 1.0 |
| NWC/Revenue: 44.75% < 20% (prev 24.88%; Δ 19.86% < -1%) |
| CFO/TA 0.09 > 3% & CFO 70.3m > Net Income 43.5m |
| Net Debt (-71.3k) to EBITDA (43.5m): -0.00 < 3 |
| Current Ratio: 153.7 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (13.3m) vs prev -4.94% < -2% |
| Gross Margin: 89.79% > 18% (prev 3.52%; Δ 8627 % > 0.5%) |
| Asset Turnover: 8.54% > 50% (prev 1.35%; Δ 7.19% > 0%) |
| Interest Coverage Ratio: -100.0k > 6 (EBITDA TTM 43.5m / Interest Expense TTM 78.0) |
Altman Z'' 10.00
| A: 0.03 (Total Current Assets 26.6m - Total Current Liabilities 172.8k) / Total Assets 774.6m |
| B: -0.22 (Retained Earnings -173.5m / Total Assets 774.6m) |
| C: -0.03 (EBIT TTM -21.5m / Avg Total Assets 690.4m) |
| D: 129.5 (Book Value of Equity 768.6m / Total Liabilities 5.93m) |
| Altman-Z'' Score: 135.3 = AAA |
Beneish M
| DSRI: 0.07 (Receivables 1.20m/2.37m, Revenue 59.0m/8.19m) |
| GMI: 3.92 (GM 89.79% / 352.4%) |
| AQI: none (AQ_t none / AQ_t-1 none) |
| SGI: 7.20 (Revenue 59.0m / 8.19m) |
| TATA: -0.03 (NI 43.5m - CFO 70.3m) / TA 774.6m) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of BMEZ shares?
As of March 11, 2026, the stock is trading at USD 14.61 with a total of 129,693 shares traded.
Over the past week, the price has changed by -0.48%, over one month by -2.33%, over three months by -2.02% and over the past year by +7.41%.
Over the past week, the price has changed by -0.48%, over one month by -2.33%, over three months by -2.02% and over the past year by +7.41%.
Is BMEZ a buy, sell or hold?
BlackRock Health Sciences has no consensus analysts rating.
What are the forecasts/targets for the BMEZ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
BMEZ Fundamental Data Overview March 08, 2026
P/S = 23.3725
P/B = 0.9525
Revenue TTM = 59.0m USD
EBIT TTM = -21.5m USD
EBITDA TTM = 43.5m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 278.1k USD (from shortTermDebt, last quarter)
Debt = 278.1k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -71.3k USD (from netDebt column, last quarter)
Enterprise Value = 1.44b USD (1.47b + Debt 278.1k - CCE 26.6m)
Interest Coverage Ratio = -276.2k (Ebit TTM -21.5m / Interest Expense TTM 78.0)
EV/FCF = 20.56x (Enterprise Value 1.44b / FCF TTM 70.3m)
FCF Yield = 4.86% (FCF TTM 70.3m / Enterprise Value 1.44b)
FCF Margin = 119.2% (FCF TTM 70.3m / Revenue TTM 59.0m)
Net Margin = 73.72% (Net Income TTM 43.5m / Revenue TTM 59.0m)
Gross Margin = 89.79% ((Revenue TTM 59.0m - Cost of Revenue TTM 6.02m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.87 (Enterprise Value 1.44b / Total Assets 774.6m)
Interest Expense / Debt = 0.03% (Interest Expense 78.0 / Debt 278.1k)
Taxrate = 21.0% (US default 21%)
NOPAT = -17.0m (EBIT -21.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 153.7 (out of range, set to none) (Total Current Assets 26.6m / Total Current Liabilities 172.8k)
Debt / Equity = 0.00 (Debt 278.1k / totalStockholderEquity, last quarter 768.6m)
Debt / EBITDA = -0.00 (Net Debt -71.3k / EBITDA 43.5m)
Debt / FCF = -0.00 (Net Debt -71.3k / FCF TTM 70.3m)
Total Stockholder Equity = 642.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.30% (Net Income 43.5m / Total Assets 774.6m)
RoE = 6.77% (Net Income TTM 43.5m / Total Stockholder Equity 642.6m)
RoCE = -3.35% (EBIT -21.5m / Capital Employed (Equity 642.6m + L.T.Debt 0.0))
RoIC = -2.29% (negative operating profit) (NOPAT -17.0m / Invested Capital 742.3m)
WACC = 8.48% (E(1.47b)/V(1.47b) * Re(8.48%) + D(278.1k)/V(1.47b) * Rd(0.03%) * (1-Tc(0.21)))
Discount Rate = 8.48% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -58.80%
[DCF] Terminal Value 79.72% ; FCFF base≈55.0m ; Y1≈67.8m ; Y5≈115.5m
[DCF] Fair Price = 28.47 (EV 1.78b - Net Debt -71.3k = Equity 1.78b / Shares 62.5m; r=8.48% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -2.05 | EPS CAGR: 60.44% | SUE: N/A | # QB: 0
Revenue Correlation: -17.93 | Revenue CAGR: 67.56% | SUE: N/A | # QB: 0
P/B = 0.9525
Revenue TTM = 59.0m USD
EBIT TTM = -21.5m USD
EBITDA TTM = 43.5m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 278.1k USD (from shortTermDebt, last quarter)
Debt = 278.1k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -71.3k USD (from netDebt column, last quarter)
Enterprise Value = 1.44b USD (1.47b + Debt 278.1k - CCE 26.6m)
Interest Coverage Ratio = -276.2k (Ebit TTM -21.5m / Interest Expense TTM 78.0)
EV/FCF = 20.56x (Enterprise Value 1.44b / FCF TTM 70.3m)
FCF Yield = 4.86% (FCF TTM 70.3m / Enterprise Value 1.44b)
FCF Margin = 119.2% (FCF TTM 70.3m / Revenue TTM 59.0m)
Net Margin = 73.72% (Net Income TTM 43.5m / Revenue TTM 59.0m)
Gross Margin = 89.79% ((Revenue TTM 59.0m - Cost of Revenue TTM 6.02m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.87 (Enterprise Value 1.44b / Total Assets 774.6m)
Interest Expense / Debt = 0.03% (Interest Expense 78.0 / Debt 278.1k)
Taxrate = 21.0% (US default 21%)
NOPAT = -17.0m (EBIT -21.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 153.7 (out of range, set to none) (Total Current Assets 26.6m / Total Current Liabilities 172.8k)
Debt / Equity = 0.00 (Debt 278.1k / totalStockholderEquity, last quarter 768.6m)
Debt / EBITDA = -0.00 (Net Debt -71.3k / EBITDA 43.5m)
Debt / FCF = -0.00 (Net Debt -71.3k / FCF TTM 70.3m)
Total Stockholder Equity = 642.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.30% (Net Income 43.5m / Total Assets 774.6m)
RoE = 6.77% (Net Income TTM 43.5m / Total Stockholder Equity 642.6m)
RoCE = -3.35% (EBIT -21.5m / Capital Employed (Equity 642.6m + L.T.Debt 0.0))
RoIC = -2.29% (negative operating profit) (NOPAT -17.0m / Invested Capital 742.3m)
WACC = 8.48% (E(1.47b)/V(1.47b) * Re(8.48%) + D(278.1k)/V(1.47b) * Rd(0.03%) * (1-Tc(0.21)))
Discount Rate = 8.48% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -58.80%
[DCF] Terminal Value 79.72% ; FCFF base≈55.0m ; Y1≈67.8m ; Y5≈115.5m
[DCF] Fair Price = 28.47 (EV 1.78b - Net Debt -71.3k = Equity 1.78b / Shares 62.5m; r=8.48% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -2.05 | EPS CAGR: 60.44% | SUE: N/A | # QB: 0
Revenue Correlation: -17.93 | Revenue CAGR: 67.56% | SUE: N/A | # QB: 0